| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/S1470-2045(00)00006-1 |
| P698 | PubMed publication ID | 11905684 |
| P2093 | author name string | W A Denny | |
| P2860 | cites work | Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs | Q36115429 |
| Tirapazamine-cisplatin: the synergy | Q36291599 | ||
| Involvement of DT-diaphorase (EC 1.6.99.2) in the DNA cross-linking and sequence selectivity of the bioreductive anti-tumour agent EO9 | Q36431639 | ||
| Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin | Q36618010 | ||
| Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). | Q40848113 | ||
| The bioactivation of CB 1954 and its use as a prodrug in antibody-directed enzyme prodrug therapy (ADEPT). | Q40848135 | ||
| A 2-nitroimidazole carbamate prodrug of 5-amimo-1-(chloromethyl)-3-[(5,6,7-trimethoxyindol-2-yl)carbony l]-1,2-dihydro-3H--benz[E]indole (amino-seco-CBI-TMI) for use with ADEPT and GDEPT. | Q40932654 | ||
| Exploring the mechanistic aspects of mitomycin antibiotic bioactivation in Chinese hamster ovary cells overexpressing NADPH:cytochrome C (P-450) reductase and DT-diaphorase | Q41004810 | ||
| The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity | Q41735615 | ||
| AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo | Q41844441 | ||
| Therapeutic advantage of hypoxic cells in tumors: a theoretical study | Q43487575 | ||
| Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck | Q44740191 | ||
| Extravascular diffusion of tirapazamine: effect of metabolic consumption assessed using the multicellular layer model. | Q52231893 | ||
| Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study | Q61889942 | ||
| Transmural Coupling of Fluid Flow in Microcirculatory Network and Interstitium in Tumors | Q62470814 | ||
| Hypoxia-selective antitumor agents. 7. Metal complexes of aliphatic mustards as a new class of hypoxia-selective cytotoxins. Synthesis and evaluation of cobalt(III) complexes of bidentate mustards | Q70771284 | ||
| Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts | Q71258131 | ||
| Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1'-radical in single-stranded and double-stranded DNA: the drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions | Q73205460 | ||
| Phase I trial with weekly EO9, a novel bioreductive alkylating indoloquinone, by the EORTC Early Clinical Study Group (ECSG) | Q73384948 | ||
| Retinal degeneration in rats induced by CI-1010, a 2-nitroimidazole radiosensitizer | Q74455457 | ||
| Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug | Q77654045 | ||
| Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: a Phase II study | Q77654078 | ||
| P433 | issue | 1 | |
| P921 | main subject | hypoxia | Q105688 |
| P304 | page(s) | 25-29 | |
| P577 | publication date | 2000-09-01 | |
| P1433 | published in | Lancet Oncology Commission | Q13747613 |
| P1476 | title | The role of hypoxia-activated prodrugs in cancer therapy | |
| P478 | volume | 1 |
| Q48577010 | A coelenterazine-type bioluminescent probe for nitroreductase imaging |
| Q38952400 | Biological evaluation of the activity of some benzimidazole-4,7-dione derivatives |
| Q38120850 | Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia |
| Q48013511 | Bioreductively activatable prodrug conjugates of phenstatin designed to target tumor hypoxia. |
| Q90119301 | Cellular adaptation to hypoxia through hypoxia inducible factors and beyond |
| Q39991099 | Cellular uptake and distribution of cobalt complexes of fluorescent ligands |
| Q39299094 | Cobalt complexes with tripodal ligands: implications for the design of drug chaperones |
| Q39877795 | Comparison of the cytotoxic effect of lapachol, alpha-lapachone and pentacyclic 1,4-naphthoquinones on human leukemic cells |
| Q36026792 | Comparison of the nucleic acid covalent binding capacity of two nitro-substituted benzazolo[3,2-a]quinolinium salts upon enzymatic reduction |
| Q35707721 | DNA strand cleaving properties and hypoxia-selective cytotoxicity of 7-chloro-2-thienylcarbonyl-3-trifluoromethylquinoxaline 1,4-dioxide |
| Q41808209 | DNA strand damage product analysis provides evidence that the tumor cell-specific cytotoxin tirapazamine produces hydroxyl radical and acts as a surrogate for O(2). |
| Q38672565 | Effect of hypoxia-inducible factors in normal and leukemic stem cell regulation and their potential therapeutic impact. |
| Q30353295 | Effect of stereotactic radiosurgery on lipids and proteins of normal and hypoperfused rat brain homogenates: a Fourier transform infrared spectroscopy study. |
| Q35851502 | Electronic structures and spin topologies of gamma-picoliniumyl radicals. A study of the homolysis of N-methyl-gamma-picolinium and of benzo-, dibenzo-, and naphthoannulated analogs |
| Q51487132 | Fluorine-18 radiolabeling of a nitrophenyl sulfoxide and its evaluation in an SK-RC-52 model of tumor hypoxia. |
| Q42813138 | Hexamethyldisiloxane-based nanoprobes for (1) H MRI oximetry |
| Q36787650 | Hypoxia-specific drug tirapazamine does not abrogate hypoxic tumor cells in combination therapy with irinotecan and methylselenocysteine in well-differentiated human head and neck squamous cell carcinoma a253 xenografts |
| Q39002822 | Hypoxia: A Double-Edged Sword in Cancer Therapy |
| Q34932613 | Impact of a low-oxygen environment on the efficacy of antimicrobials against intracellular Chlamydia trachomatis. |
| Q37594215 | Increased chemosensitivity and radiosensitivity of human breast cancer cell lines treated with novel functionalized single-walled carbon nanotubes |
| Q28553729 | Leveraging Hypoxia-Activated Prodrugs to Prevent Drug Resistance in Solid Tumors |
| Q57804227 | Mathematical Modelling of a Hypoxia-regulated Oncolytic Virus Delivered by Tumour-associated Macrophages |
| Q38961080 | Modulating tumor hypoxia by nanomedicine for effective cancer therapy |
| Q35920685 | Modulation of the tumor vasculature and oxygenation to improve therapy |
| Q35390655 | Novel Phenazine 5,10-Dioxides Release OH in Simulated Hypoxia and Induce Reduction of Tumour Volume In Vivo. |
| Q35307851 | Optimizing therapeutic efficacy of chemopreventive agents: A critical review of delivery strategies in oral cancer chemoprevention clinical trials. |
| Q64073411 | Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy |
| Q48354965 | Recent development of luminescent rhenium(i) tricarbonyl polypyridine complexes as cellular imaging reagents, anticancer drugs, and antibacterial agents. |
| Q33365148 | Role of the nitro functionality in the DNA binding of 3-nitro-10-methylbenzothiazolo[3,2-a]quinolinium chloride |
| Q46679625 | Synthesis, Preferentially Hypoxic Apoptosis and Anti-Angiogenic Activity of 3-Amino-1,2,4-Benzotriazine-1,4-Dioxide Bearing Alkyl Linkers with a 3-Amino-1,2,4-Benzotriazine-1-Oxide Moiety |
| Q95791918 | Synthesis, anticancer activity and UPLC analysis of the stability of some new benzimidazole-4,7-dione derivatives |
| Q37565506 | The anti-tumor efficacy of 3-(2-Nitrophenyl) propionic acid-paclitaxel (NPPA-PTX): a novel paclitaxel bioreductive prodrug |
| Q37377149 | The importance of radiation chemistry to radiation and free radical biology (The 2008 Silvanus Thompson Memorial Lecture). |
| Q35968111 | The role of functional and molecular imaging in cancer drug discovery and development |
| Q48114384 | Theranostic Liposomes with Hypoxia-Activated Prodrug to Effectively Destruct Hypoxic Tumors Post-Photodynamic Therapy. |
| Q26747806 | Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer |
| Q36634689 | Transplantation of tissue-engineered human corneal endothelium in cat models |
Search more.